Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity

Guo, ZS and Liu, Z and Bartlett, DL (2014) Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Frontiers in Oncology, 4 APR.

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (856kB)
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Oncolytic viruses (OVs) are novel immunotherapeutic agents whose anticancer effects come from both oncolysis and elicited antitumor immunity. OVs induce mostly immunogenic cancer cell death (ICD), including immunogenic apoptosis, necrosis/necroptosis, pyroptosis, and autophagic cell death, leading to exposure of calreticulin and heat-shock proteins to the cell surface, and/or released ATP, high-mobility group box 1, uric acid, and other damage-associated molecular patterns as well as pathogen-associated molecular patterns as danger signals, along with tumor-associated antigens, to activate dendritic cells and elicit adaptive antitumor immunity. Dying the right way may greatly potentiate adaptive antitumor immunity. The mode of cancer cell death may be modulated by individual OVs and cancer cells as they often encode and express genes that inhibit/promote apoptosis, necroptosis, or autophagic cell death. We can genetically engineer OVs with death-pathway-modulating genes and thus skew the infected cancer cells toward certain death pathways for the enhanced immunogenicity. Strategies combining with some standard therapeutic regimens may also change the immunological consequence of cancer cell death. In this review, we discuss recent advances in our understanding of danger signals, modes of cancer cell death induced by OVs, the induced danger signals and functions in eliciting subsequent antitumor immunity. We also discuss potential combination strategies to target cells into specific modes of ICD and enhance cancer immunogenicity, including blockade of immune checkpoints, in order to break immune tolerance, improve antitumor immunity, and thus the overall therapeutic efficacy. © 2014 Guo, Liu and Bartlett.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Guo, ZSzsg2@pitt.eduZSG2
Liu, Zzul2@pitt.eduZUL2
Bartlett, DLdlb3@pitt.eduDLB3
Centers: Other Centers, Institutes, Offices, or Units > Hillman Cancer Center
Date: 1 January 2014
Date Type: Publication
Journal or Publication Title: Frontiers in Oncology
Volume: 4 APR
DOI or Unique Handle: 10.3389/fonc.2014.00074
Schools and Programs: School of Medicine > Surgery
Refereed: Yes
Article Type: Review
Date Deposited: 01 Jun 2015 20:56
Last Modified: 26 Jan 2019 10:55
URI: http://d-scholarship.pitt.edu/id/eprint/24849

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item